Navigation Links
Mylan's Matrix Receives FDA Approval Under PEPFAR for Zidovudine Tablets, 100 mg
Date:3/10/2011

The water-dispersible tablet is unique because it can be dispersed in water for all patients, adults or children, who are unable to swallow tablets.

Matrix's wide range of ARV products includes active pharmaceutical ingredients and 35 first- and second-line finished doses, nine of which are pediatric products. The company's emphasis on producing affordable products has allowed it to drive down the average annual cost per patient of effective therapies. Approximately 30% of HIV/AIDS patients in developing countries depend on a Matrix ARV product.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
2. BioNanomatrix Founder and CSO Dr. Han Cao Awarded Chinese Rising Star Entrepreneur Award
3. Collagen Matrix, Inc. Receives FDA 510(k) Clearance for New Collagen Dental Membrane Based on Porcine Collagen Platform Technology
4. Human Embryonic-Like Extracellular Matrix Significantly Inhibits Tumor Growth and Cancer Cell Proliferation
5. TriReme Medical, Inc. Receives FDA 510(k) Clearance for a Broad Matrix of GliderXtreme(TM) PTA Balloon Catheter Sizes
6. Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
7. TEI Biosciences PriMatrix(TM) Awarded Seal of Approval by American Podiatric Medical Association
8. Osteotech Submits 510(k) Application to FDA for Clearance of its Duratech(TM) BioRegeneration Matrix
9. BioNanomatrix Awarded Supplemental Funding to Accelerate Commercialization of Innovative Single-Molecule Analyzer
10. Brennen Medical Announces Sale of XenMatrix(R)
11. BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 2015  For about a century, a known ... to utilize and catabolize glucose at a high ... called the ,Warburg phenomenon", that is an increased ... presence, leading to enhanced lactate generation. Even under ... glucose fermentation. A variety of such abnormalities have ...
(Date:4/27/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the year ended December 31, 2014. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... not provide the outcome management and investors had ... iCo Therapeutics", said Andrew Rae , President ...
(Date:4/27/2015)... HEIDELBERG , Alemania, April 27, 2015 /PRNewswire/ ... para un nuevo receptor utilizando tecnología de descubrimiento de ... cubierta en el tratamiento de millones de pacientes con ... hoy que ha recibido una patente en Europa titulada ... descubrimiento de Molecular Health de que EPHB4 es un ...
(Date:4/27/2015)... Dr. Robert Hanzlik, whose groundbreaking research into ... for advancing the creation of safer pharmaceuticals, will be ... , the second-largest private, nonprofit university in California. , ... at the University of Kansas School of Pharmacy who ... 5 p.m. and takes place at National University’s Torrey ...
Breaking Biology Technology:Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3
... , , PRINCETON, N.J., July 24 ... companies from around the world who gather at InformexUSA 2010 will ... past, allowing them to connect more precisely with others in their ... The show opens February 16, 2010 in San Francisco, with a ...
... , SILVER SPRING, Md., July 24 ... that it will release its 2009 second quarter financial results ... , United Therapeutics Corporation will host ... a.m. Eastern Time. The teleconference is accessible by dialing ...
... ... offers Fetal Bovine Serum (FBS) originating from abattoirs located in the US, ... treatments such as heat inactivation, dialysis, or gamma irradiation are available as ... FBS for embryonic stem cell research. Each FBS order includes a ...
Cached Biology Technology:Informex Rebrands Into Separate Pharmaceutical and Specialty Chemical Segments to Better Serve Exhibitors and Attendees 2Informex Rebrands Into Separate Pharmaceutical and Specialty Chemical Segments to Better Serve Exhibitors and Attendees 3Spectrum Announces Fetal Bovine Serum Product Line 2
(Date:4/27/2015)... 2015 Profile Solutions, Inc. (OTC: PSIQ), a ... is pleased to announce that Dr Gerry Bedore ... member of its scientific advisory board. ... thought leader in technology-enhanced learning models. He was a ... published studies and books focused on online student success ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2
... that the effects of prion disease could be reversed ... findings support developing early treatments that aim to reduce ... with prion disease. Also, they said that their findings ... way: by analyzing their cognitive effects in prion-infected mice. ...
... autopsy data provide the strongest evidence yet that sudden infant ... a concrete biological basis. In the November 1 issue of ... brainstem ?a part of the brain that regulates breathing, blood ... SIDS. , SIDS is the leading cause of death ...
... Jude Children's Research Hospital have demonstrated in a mouse model ... that not only greatly reduces the size of the tumor, ... standard chemotherapy. The treatment also appears to be suitable for ... is simple enough for widespread use even in countries with ...
Cached Biology News:Prion disease treatable if caught early 2A potential biological cause for sudden infant death syndrome 2A potential biological cause for sudden infant death syndrome 3St. Jude announces breakthrough in eye cancer treatment 2St. Jude announces breakthrough in eye cancer treatment 3St. Jude announces breakthrough in eye cancer treatment 4
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
Rabbit polyclonal to Orexin Prepro ( Abpromise for all tested applications). entrezGeneID: 3060 SwissProtID: O43612...
Anti-human C5a/C5a des-Arg (neo-epitode), Clone 2952, Monoclonal Antibody...
Ubiquitin-conjugating enzyme E2N...
Biology Products: